For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website: http://www.visiongain.com/Report/1126/World-Vaccines-Market-2013-2023
Global lung cancer vaccine market & pipeline outlook 2022Rajesh Sarma
“Global Lung Cancer Vaccine Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are 9 lung cancer vaccines in advance Phase-II clinical trials followed by 8 vaccines Phase-I/II trials.
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
Global gene therapy market & pipeline insightKuicK Research
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
Gene Therapy Market Overview
Significance of Gene Therapy in Cancer Therapeutics
Current Applications of Gene Therapy to Cancer Treatment
Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
FDA & AMA Guidelines for Gene Therapy
Gene Therapy Pipeline by Phase, Indications, Country & Company
Gene Therapy Pipeline: 246 Drugs
Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
Cancer Gene Therapy Pipeline: 69 Drugs
Global insulin patch market opportunity analysisKuicK Research
This document analyzes the global insulin patch market opportunity. It discusses how insulin patches provide a controlled release of insulin through the skin to help manage diabetes. Insulin patches are still under development and use various technologies like iontophoresis, ultrasound, and microneedles to transfer insulin across the skin. The market is expected to grow as patches offer benefits over other insulin delivery methods and more indications are explored. However, development and commercialization of insulin patches also faces challenges related to costs and limited availability. Overall, the global insulin patch market presents significant opportunities as the technology advances and more effective patches are introduced.
“Global HIV Infection Drug Market & Pipeline Insight” Report Highlight:
Global HIV Infection Drug Market Overview & Incidence Scenario
FDA & EMA Regulation for Development of HIV Drug
Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
Global HIV Clinical Pipeline: 315 Drugs in Development Phases
Majority HIV Drug in Preclinical Phase: 144 Drugs
Marketed HIV Drugs: 37
Suspended & Discounted HIV Drug in Clinical Pipeline: 539 Drugs
Patent Analysis: Patent Number & Technology
Global lung cancer vaccine market & pipeline outlook 2022Rajesh Sarma
“Global Lung Cancer Vaccine Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are 9 lung cancer vaccines in advance Phase-II clinical trials followed by 8 vaccines Phase-I/II trials.
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
Global gene therapy market & pipeline insightKuicK Research
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
Gene Therapy Market Overview
Significance of Gene Therapy in Cancer Therapeutics
Current Applications of Gene Therapy to Cancer Treatment
Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
FDA & AMA Guidelines for Gene Therapy
Gene Therapy Pipeline by Phase, Indications, Country & Company
Gene Therapy Pipeline: 246 Drugs
Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
Cancer Gene Therapy Pipeline: 69 Drugs
Global insulin patch market opportunity analysisKuicK Research
This document analyzes the global insulin patch market opportunity. It discusses how insulin patches provide a controlled release of insulin through the skin to help manage diabetes. Insulin patches are still under development and use various technologies like iontophoresis, ultrasound, and microneedles to transfer insulin across the skin. The market is expected to grow as patches offer benefits over other insulin delivery methods and more indications are explored. However, development and commercialization of insulin patches also faces challenges related to costs and limited availability. Overall, the global insulin patch market presents significant opportunities as the technology advances and more effective patches are introduced.
“Global HIV Infection Drug Market & Pipeline Insight” Report Highlight:
Global HIV Infection Drug Market Overview & Incidence Scenario
FDA & EMA Regulation for Development of HIV Drug
Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
Global HIV Clinical Pipeline: 315 Drugs in Development Phases
Majority HIV Drug in Preclinical Phase: 144 Drugs
Marketed HIV Drugs: 37
Suspended & Discounted HIV Drug in Clinical Pipeline: 539 Drugs
Patent Analysis: Patent Number & Technology
Global vaccine adjuvants market research report 2017QYResearch
The document discusses the global vaccine adjuvants market. It provides information on market size, segmentation by type and application, key manufacturers, and forecasts for market growth between 2017-2022. Some key points:
- The global vaccine adjuvants market is expected to reach $920 million by 2022, growing at a CAGR of 10.3% annually from $560 million in 2017.
- The market is segmented into veterinary and human vaccine adjuvants. It is further divided by type (e.g. oral, subcutaneous) and application (e.g. research, commercial).
- Major manufacturers of veterinary adjuvants include SEPPIC, SDA BIO, Brenntag Biosector,
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...KuicK Research
This document provides an overview of the global cancer tyrosine kinase inhibitors market and clinical pipeline outlook for 2020. It discusses tyrosine kinases' role in cancer signaling pathways and the development of tyrosine kinase inhibitors as targeted cancer therapies. The market for tyrosine kinase inhibitors is growing due to rising cancer incidence and a strong clinical pipeline. Over 400 tyrosine kinase inhibitors are in clinical development globally across various phases of trials. The future outlook for tyrosine kinase inhibitors is optimistic due to ongoing research and advancement in development approaches.
We Analyzed 1 Million Articles about Covid Vaccines. Here’s What We Found!Social Animal
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.
Ever since The World Health Organization (WHO) declared the Coronavirus outbreak as a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020, scientists from all over the world have been scrambling to create a vaccine.
During this period, vaccine development was expedited and scientists faced various challenges in creating a working vaccine.
The urgency to create a vaccine led to “compressed schedules” where trials for vaccines, which usually take years, were conducted over a period of months.
Since then, Several vaccines have been approved for mass vaccination drives against COVID-19 and have been distributed globally.
However, the community’s knowledge, attitudes, and perceptions towards these vaccinations are poorly understood.
We analyzed 1M articles that contained the mentions of various vaccines and here’s what we found.
✔✔ Conversations about Pfizer have received more engagement on Twitter as Pfizer has shown the highest efficacy rate of 95%.
✔✔ Moderna has an efficacy of 94.1% against covid infection and the engagement shows that articles that mention Moderna had lesser engagement than Pfizer but considerably more than other vaccines.
✔✔ AstraZeneca ranks third when it comes to Twitter engagement among popular vaccines.
✔✔ Russia’s Sputnik vaccine claims a 95% efficacy rate, even before beginning a Phase III trial. But conversations and engagement on Twitter have been minimal.
✔✔ Covaxin and Novavax have had some conversations and mentions on Twitter, unlike Janssen, a vaccine that has had the least engagement.
You can find more interesting data in our report!
Biochip Market - Overview and Growth ReportSignitech
Global biochip market was valued at USD 7.63 billion in 2015. Presence of strong demand for proteomics - and genomics research-oriented products along with a comprehensive drug development pipeline is expected to drive growth in revenue.
The document discusses the present and future of the vaccine industry. It provides an overview of key topics like growth drivers, challenges, SWOT analysis and future developments. The vaccine industry is growing at 10-13% annually and will be valued at $1.4-1.8 billion in India by 2020. New vaccines are being developed for diseases like dengue, malaria and tuberculosis. Adjuvants and conjugate vaccines may help increase efficacy for elderly populations. Future areas of focus include adult vaccines, novel delivery methods, and harnessing new technologies.
"US Cancer Vaccine Market Outlook 2020" Report Highlight:
US Cancer Vaccine Market Analysis
Cancer Vaccine with Orphan Status
US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
US Cancer Vaccine Clinical Pipeline: 187 Vaccines
Clinical Insight of Marketed Cancer Vaccines in US
Marketed Cancer Vaccine in US: 5 Vaccines
FDA Regulations for Clinical Trials of Cancer Vaccines
In this section of the coronavirus pandemic series, we discuss the need for an effective COVID-19 vaccine to return to full normalcy. The slides would give a brief overview on how our immune systems work, and how a vaccine would train our immune system to recognize and fight the infection. Current vaccine platform technologies will be compared, and upcoming candidates will be highlighted for newer-generation vaccines. We'll also discuss in-depth on factors involving vaccine manufacturing, hesitancy & acceptance, and contingencies. The market capitalization of pharma companies involved in the development of the coronavirus vaccine will also be compared.
The transient protein expression market was valued at US$ 660.00 million in 2019 and is projected to reach US$ 983.10 million by 2027; it is expected to grow at a CAGR of 5.3% from 2020 to 2027.
"US Cancer Vaccine Market Outlook 2020" Report Highlight:
US Cancer Vaccine Market Analysis
Cancer Vaccine with Orphan Status
US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
US Cancer Vaccine Clinical Pipeline: 187 Vaccines
Clinical Insight of Marketed Cancer Vaccines in US
Marketed Cancer Vaccine in US: 5 Vaccines
FDA Regulations for Clinical Trials of Cancer Vaccines
Vaccines 2012 World Market Analysis, Key Players, Trends, Pediatric and Adult...ReportsnReports
This 249-page report examines the global vaccine market, including key trends, players, and forecasts for pediatric and adult vaccine segments from 2007-2016. It covers commercialized and developmental vaccines for diseases like hepatitis, HIB, MMR, pneumococcal, polio, varicella, cervical cancer, influenza, and pneumococcal. The market is growing due to new product introductions and rising usage worldwide. Major players profiled include GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, Novartis, Emergent Biosolutions, MedImmune, Crucell, Bavarian Nordic, Baxter, Bharat Biotech, and AlphaVax. Issues
Download Global breast cancer vaccine market & clinical pipeline outlook ...KuicK Research
“Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of the breast cancer vaccines in clinical trials are in preclinical phase followed by Phase-I trials. The advance stage of development of breast cancer vaccine in clinical trials across the globe is in Phase-III.
The conventional cancer treatment methods have proved their importance in last decade. They are widely accepted among patients and physicians (oncologists) because of familiarity and large amount of statistically significant data supporting their efficacy. Despite their benefits, they sometimes fall short in meeting the patient’s personal requirements. For instance, efficacy is a major requirement, but different patients display different response to the same medication, this is attributed to their unique genetic makeup. To meet the individual’s necessities, high efficacy and safety, concept of cancer vaccine was formulated.
The document discusses key trends in the global vaccine market:
1) The vaccine market has tripled in value since 2000 to nearly $24 billion in 2013 and is projected to reach $100 billion by 2025 due to new product development and increased demand.
2) Five large multi-national corporations dominate 80% of the global market, but emerging manufacturers are playing a larger role in developing countries which represent 80% of the population but less than 20% of sales.
3) UN procurement of vaccines through UNICEF and PAHO has increased over 400% since 2002, now representing around 7.5% of total vaccine sales and driving demand for new products.
Public perception on COVID-19 Vaccine(AstraZeneca) uptake presentation-Simon ...SimonMwaringa
This study investigated perceptions of the Covid-19 vaccine and vaccine uptake at the University of Eldoret in Kenya. An online survey was administered to 200 respondents and the data was analyzed using SPSS and Excel. The study found that while most respondents had some knowledge of vaccines, vaccination rates remained low. There were also significant safety concerns and the influence of conspiracy theories. The researchers recommend increasing education efforts through various platforms, with a focus on addressing gender differences, regularly sharing evidence-based research on hesitancy, and integrating immunization programs on campus and in the community.
EVE198 Fall2020 "Covid Mass Testing" Class 8 VaccinesJonathan Eisen
This document discusses a class on vaccines for COVID-19. It covers topics like vaccine development, current candidate vaccines, challenges with vaccine distribution, and how vaccines are being assessed for safety, effectiveness, costs and production feasibility. Over 100 vaccine candidates are in development using platforms like DNA, RNA, viral vectors and inactivated viruses. Efforts like Operation Warp Speed are coordinating development of nucleic acid, viral vector and protein subunit vaccines. Distribution challenges include vaccine production, storage and logistics, number of doses required, and overcoming vaccine nationalism and hesitancy.
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
EVE198 Winter2020 Class 5 - COVID VaccinesJonathan Eisen
The document discusses a class on COVID-19 vaccines. It covers topics like vaccine development, current candidates, delivery challenges, and comparisons between vaccines. Moderna and Pfizer mRNA vaccines are highlighted as being similar but having some differences in mRNA region, nanoparticle structure/synthesis, dosage amount, and storage temperature requirements. Other vaccines discussed include Novavax using spike protein nanoparticles, and AstraZeneca and Johnson & Johnson using DNA for spike protein delivered by a modified virus.
Global cancer vaccine market & pipeline analysisKuicK Research
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
A recent report from Renub Research, titled "Global Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028," offers a thorough analysis of the industry and market share knowledge. The report also includes research on regions, competitors, and the recent expansion of the Global Vaccine Market.
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:
Introduction to Lung Cancer Vaccine
Global Lung Cancer Vaccine Market Analysis
Global Lung Cancer Vaccine Pipeline by Company & Phase
Global Lung Cancer Vaccine Pipeline: 29 Vaccines
Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C™ & Vaxira®)
Personalized Cancer Vaccines: Progress & Possibilities
Lung Cancer Vaccine Mechanism
Global vaccine adjuvants market research report 2017QYResearch
The document discusses the global vaccine adjuvants market. It provides information on market size, segmentation by type and application, key manufacturers, and forecasts for market growth between 2017-2022. Some key points:
- The global vaccine adjuvants market is expected to reach $920 million by 2022, growing at a CAGR of 10.3% annually from $560 million in 2017.
- The market is segmented into veterinary and human vaccine adjuvants. It is further divided by type (e.g. oral, subcutaneous) and application (e.g. research, commercial).
- Major manufacturers of veterinary adjuvants include SEPPIC, SDA BIO, Brenntag Biosector,
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...KuicK Research
This document provides an overview of the global cancer tyrosine kinase inhibitors market and clinical pipeline outlook for 2020. It discusses tyrosine kinases' role in cancer signaling pathways and the development of tyrosine kinase inhibitors as targeted cancer therapies. The market for tyrosine kinase inhibitors is growing due to rising cancer incidence and a strong clinical pipeline. Over 400 tyrosine kinase inhibitors are in clinical development globally across various phases of trials. The future outlook for tyrosine kinase inhibitors is optimistic due to ongoing research and advancement in development approaches.
We Analyzed 1 Million Articles about Covid Vaccines. Here’s What We Found!Social Animal
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.
Ever since The World Health Organization (WHO) declared the Coronavirus outbreak as a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020, scientists from all over the world have been scrambling to create a vaccine.
During this period, vaccine development was expedited and scientists faced various challenges in creating a working vaccine.
The urgency to create a vaccine led to “compressed schedules” where trials for vaccines, which usually take years, were conducted over a period of months.
Since then, Several vaccines have been approved for mass vaccination drives against COVID-19 and have been distributed globally.
However, the community’s knowledge, attitudes, and perceptions towards these vaccinations are poorly understood.
We analyzed 1M articles that contained the mentions of various vaccines and here’s what we found.
✔✔ Conversations about Pfizer have received more engagement on Twitter as Pfizer has shown the highest efficacy rate of 95%.
✔✔ Moderna has an efficacy of 94.1% against covid infection and the engagement shows that articles that mention Moderna had lesser engagement than Pfizer but considerably more than other vaccines.
✔✔ AstraZeneca ranks third when it comes to Twitter engagement among popular vaccines.
✔✔ Russia’s Sputnik vaccine claims a 95% efficacy rate, even before beginning a Phase III trial. But conversations and engagement on Twitter have been minimal.
✔✔ Covaxin and Novavax have had some conversations and mentions on Twitter, unlike Janssen, a vaccine that has had the least engagement.
You can find more interesting data in our report!
Biochip Market - Overview and Growth ReportSignitech
Global biochip market was valued at USD 7.63 billion in 2015. Presence of strong demand for proteomics - and genomics research-oriented products along with a comprehensive drug development pipeline is expected to drive growth in revenue.
The document discusses the present and future of the vaccine industry. It provides an overview of key topics like growth drivers, challenges, SWOT analysis and future developments. The vaccine industry is growing at 10-13% annually and will be valued at $1.4-1.8 billion in India by 2020. New vaccines are being developed for diseases like dengue, malaria and tuberculosis. Adjuvants and conjugate vaccines may help increase efficacy for elderly populations. Future areas of focus include adult vaccines, novel delivery methods, and harnessing new technologies.
"US Cancer Vaccine Market Outlook 2020" Report Highlight:
US Cancer Vaccine Market Analysis
Cancer Vaccine with Orphan Status
US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
US Cancer Vaccine Clinical Pipeline: 187 Vaccines
Clinical Insight of Marketed Cancer Vaccines in US
Marketed Cancer Vaccine in US: 5 Vaccines
FDA Regulations for Clinical Trials of Cancer Vaccines
In this section of the coronavirus pandemic series, we discuss the need for an effective COVID-19 vaccine to return to full normalcy. The slides would give a brief overview on how our immune systems work, and how a vaccine would train our immune system to recognize and fight the infection. Current vaccine platform technologies will be compared, and upcoming candidates will be highlighted for newer-generation vaccines. We'll also discuss in-depth on factors involving vaccine manufacturing, hesitancy & acceptance, and contingencies. The market capitalization of pharma companies involved in the development of the coronavirus vaccine will also be compared.
The transient protein expression market was valued at US$ 660.00 million in 2019 and is projected to reach US$ 983.10 million by 2027; it is expected to grow at a CAGR of 5.3% from 2020 to 2027.
"US Cancer Vaccine Market Outlook 2020" Report Highlight:
US Cancer Vaccine Market Analysis
Cancer Vaccine with Orphan Status
US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
US Cancer Vaccine Clinical Pipeline: 187 Vaccines
Clinical Insight of Marketed Cancer Vaccines in US
Marketed Cancer Vaccine in US: 5 Vaccines
FDA Regulations for Clinical Trials of Cancer Vaccines
Vaccines 2012 World Market Analysis, Key Players, Trends, Pediatric and Adult...ReportsnReports
This 249-page report examines the global vaccine market, including key trends, players, and forecasts for pediatric and adult vaccine segments from 2007-2016. It covers commercialized and developmental vaccines for diseases like hepatitis, HIB, MMR, pneumococcal, polio, varicella, cervical cancer, influenza, and pneumococcal. The market is growing due to new product introductions and rising usage worldwide. Major players profiled include GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, Novartis, Emergent Biosolutions, MedImmune, Crucell, Bavarian Nordic, Baxter, Bharat Biotech, and AlphaVax. Issues
Download Global breast cancer vaccine market & clinical pipeline outlook ...KuicK Research
“Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of the breast cancer vaccines in clinical trials are in preclinical phase followed by Phase-I trials. The advance stage of development of breast cancer vaccine in clinical trials across the globe is in Phase-III.
The conventional cancer treatment methods have proved their importance in last decade. They are widely accepted among patients and physicians (oncologists) because of familiarity and large amount of statistically significant data supporting their efficacy. Despite their benefits, they sometimes fall short in meeting the patient’s personal requirements. For instance, efficacy is a major requirement, but different patients display different response to the same medication, this is attributed to their unique genetic makeup. To meet the individual’s necessities, high efficacy and safety, concept of cancer vaccine was formulated.
The document discusses key trends in the global vaccine market:
1) The vaccine market has tripled in value since 2000 to nearly $24 billion in 2013 and is projected to reach $100 billion by 2025 due to new product development and increased demand.
2) Five large multi-national corporations dominate 80% of the global market, but emerging manufacturers are playing a larger role in developing countries which represent 80% of the population but less than 20% of sales.
3) UN procurement of vaccines through UNICEF and PAHO has increased over 400% since 2002, now representing around 7.5% of total vaccine sales and driving demand for new products.
Public perception on COVID-19 Vaccine(AstraZeneca) uptake presentation-Simon ...SimonMwaringa
This study investigated perceptions of the Covid-19 vaccine and vaccine uptake at the University of Eldoret in Kenya. An online survey was administered to 200 respondents and the data was analyzed using SPSS and Excel. The study found that while most respondents had some knowledge of vaccines, vaccination rates remained low. There were also significant safety concerns and the influence of conspiracy theories. The researchers recommend increasing education efforts through various platforms, with a focus on addressing gender differences, regularly sharing evidence-based research on hesitancy, and integrating immunization programs on campus and in the community.
EVE198 Fall2020 "Covid Mass Testing" Class 8 VaccinesJonathan Eisen
This document discusses a class on vaccines for COVID-19. It covers topics like vaccine development, current candidate vaccines, challenges with vaccine distribution, and how vaccines are being assessed for safety, effectiveness, costs and production feasibility. Over 100 vaccine candidates are in development using platforms like DNA, RNA, viral vectors and inactivated viruses. Efforts like Operation Warp Speed are coordinating development of nucleic acid, viral vector and protein subunit vaccines. Distribution challenges include vaccine production, storage and logistics, number of doses required, and overcoming vaccine nationalism and hesitancy.
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
EVE198 Winter2020 Class 5 - COVID VaccinesJonathan Eisen
The document discusses a class on COVID-19 vaccines. It covers topics like vaccine development, current candidates, delivery challenges, and comparisons between vaccines. Moderna and Pfizer mRNA vaccines are highlighted as being similar but having some differences in mRNA region, nanoparticle structure/synthesis, dosage amount, and storage temperature requirements. Other vaccines discussed include Novavax using spike protein nanoparticles, and AstraZeneca and Johnson & Johnson using DNA for spike protein delivered by a modified virus.
Global cancer vaccine market & pipeline analysisKuicK Research
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
A recent report from Renub Research, titled "Global Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028," offers a thorough analysis of the industry and market share knowledge. The report also includes research on regions, competitors, and the recent expansion of the Global Vaccine Market.
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:
Introduction to Lung Cancer Vaccine
Global Lung Cancer Vaccine Market Analysis
Global Lung Cancer Vaccine Pipeline by Company & Phase
Global Lung Cancer Vaccine Pipeline: 29 Vaccines
Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C™ & Vaxira®)
Personalized Cancer Vaccines: Progress & Possibilities
Lung Cancer Vaccine Mechanism
Coronavirus Vaccine Market - Global Industry Size, Share, Trend, Opportunity ...TechSci Research
According to #TechSci Research report, Global Coronavirus Vaccine Market is expected to grow at a robust rate by 2026 on account of the increasing research and development activities.
Gain More Insight: https://bit.ly/3qmxDOw
Get Sample Report: https://bit.ly/3EKdlWl
Press Release: https://bit.ly/3vBIZko
Website: https://www.techsciresearch.com/
Market Research News: https://techsciblog.com/
Antithrombotic Drugs World Industry 2014-2024Visiongain
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1208/Antithrombotic-Drugs-World-Industry-and-Market-Prospects-2014-2024
Global peptide vaccine market & pipeline insightKuicK Research
Global Peptide Vaccine Market & Pipeline Insight provides an overview of the global peptide vaccine market and pipeline. Peptide vaccines work by activating the human immune system through mimicking pathogen proteins, inducing long-term immunity without showing direct pharmacological effects. The research and development of peptide vaccines has gained significant momentum in the pharmaceutical industry over the past decade due to their high safety, efficacy, and minimal side effects. The report provides details on the peptide vaccine market size and dynamics, clinical pipeline by phase and indication, and competitive landscape among major industry players. It is expected that next-generation peptide vaccines currently in development will pass regulatory approvals and clinical trials to be commercialized in the near future.
This document is a dissertation that evaluates the market potential of next-generation genetically modified (GM) vaccines to address unmet medical needs, with a focus on influenza vaccines. The dissertation conducts several studies to identify critical success factors for GM vaccines and analyze trends in GM vaccine patents, approvals, and technologies. It focuses particularly on the potential of the modified vaccinia virus Ankara (MVA) vector platform and conducts interviews with key opinion leaders in vaccine development to understand challenges to market implementation. The data suggest that vector-based GM vaccines may offer a cost-effective way to produce safe and effective vaccines for diseases that currently lack vaccines, helping fulfill an important unmet medical need.
Vaccine Adjuvants Market by Product Type, Distribution Channel, End User 2024...IMARC Group
The global vaccine adjuvants market size reached US$ 996.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,639.3 Million by 2032, exhibiting a growth rate (CAGR) of 11.1% during 2024-2032.
More Info:- https://www.imarcgroup.com/vaccine-adjuvants-market
The global gene therapy market size was valued at USD 536.43 million in 2018 and is expected to register a CAGR of 33.9% assuming the projected successful commercialization of some of the key therapeutics, that are planned over the forecast period.
Global cancer vaccines market & pipeline analysisKuicK Research
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
This document summarizes the key findings of a report on the global vaccine market forecast from 2012 to 2017. It includes an analysis of major vaccines currently on the market and in development pipelines, as well as the competitive landscape and market potential in key geographical regions such as the US, Europe, India, and China. The report methodology involved extensive secondary and primary research on vaccine manufacturers, industry reports, clinical studies and government databases to analyze market trends, size, growth opportunities and challenges in the global vaccine industry.
The Future Landscape of Covid-19 Vaccine MarketMehdiMehdiyev4
We believe that assessing the potential market for COVID-
19 vaccines is necessary in terms of reevaluating the risk/reward ratio of certain vaccine developing companies.
In addition, an overly utopian outlook for a potential COVID-19 vaccine market may lead to
disappointment and negatively affect future vaccine developers. And this concerns us more.
Next Generation Antibody Therapies World Industry 2014-2024Visiongain
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1210/Next-Generation-Antibody-Therapies-World-Industry-and-Market-2014-2024
Booster doses of COVID-19 vaccine: Rationales, implications and way forward f...BRNSSPublicationHubI
This document discusses rationales for COVID-19 vaccine booster doses in African countries. It notes that while many African countries obtained initial vaccine doses, obtaining booster doses has proven difficult. Booster doses are recommended to maintain sufficient protection against infection as immunity from initial doses wanes over time. However, African countries face challenges with weak vaccine supply chains and fragile health systems in obtaining adequate booster doses for their populations. The document examines rationales for boosters, supply issues challenging African countries, and implications and recommendations regarding boosters on the continent.
Monkeypox Vaccine Market by Product Type, Distribution Channel, End User 2024...IMARC Group
The global monkeypox vaccine market size reached US$ 86.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 421.8 Million by 2032, exhibiting a growth rate (CAGR) of 18.85% during 2024-2032.
More Info:- https://www.imarcgroup.com/monkeypox-vaccine-market
The global monoclonal antibodies market is expected to reach $148.9 billion by 2026, growing at a CAGR of 6.1%. Monoclonal antibodies are primarily used to treat cancer and other chronic diseases. The market is driven by an active drug development pipeline and increasing prevalence of diseases. North America currently dominates the market due to high healthcare spending. Major players are focusing on developing biosimilars and targeting new disease areas to boost market growth.
The global monoclonal antibodies market is expected to reach $148.9 billion by 2026, growing at a CAGR of 6.1%. Monoclonal antibodies are primarily used to treat cancer and other chronic diseases. The market is driven by an active drug development pipeline and increasing prevalence of diseases. Key players are focusing on developing biosimilars and targeting new disease areas to capitalize on market opportunities. The cancer segment currently dominates the market due to growing patient numbers and awareness. North America accounts for the largest share of the monoclonal antibodies market.
Febrile Neutropenia Market 2023: Epidemiology, Industry Trends, Size, Share A...frankmorgan27
The growing utilization of chemotherapy or radiation therapy, which can hinder the bone marrow’s ability to produce new blood cells, is primarily driving the febrile neutropenia market.
Pediatric Vaccines Market Growth, Demand and Challenges of the Key Industry P...IMARC Group
The global pediatric vaccines market size reached US$ 37.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 70.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.26% during 2024-2032.
More Info:- https://www.imarcgroup.com/pediatric-vaccines-market
Global Vaccines Market 2020 By Technology [Conjugate vaccines, Inactivated and subunit vaccines, Live attenuated vaccines, Recombinant vaccines, Toxoid vaccines and others],By Type [Monovalent vaccines, Multivalent vaccines and others], By Patient Type[Pediatric patients, Adult patients and others], By Disease[Cancer, Dengue, DTP, Hepatitis, Human Papilloma Virus, Influenza, Meningococcal Disease, Pneumococcal disease, Polio, Rotavirus and others]: Global Forecast to 2026 and COVID-19 Impact Outlook
Global Vaccines Market is valued at USD 45.9 Billion in 2019 and expected to reach USD 91.9 Billion by 2026 with the CAGR of 10.44 % over the forecast period.
Best Competitive Marble Pricing in Dubai - ☎ 9928909666Stone Art Hub
Stone Art Hub offers the best competitive Marble Pricing in Dubai, ensuring affordability without compromising quality. With a wide range of exquisite marble options to choose from, you can enhance your spaces with elegance and sophistication. For inquiries or orders, contact us at ☎ 9928909666. Experience luxury at unbeatable prices.
Easily Verify Compliance and Security with Binance KYCAny kyc Account
Use our simple KYC verification guide to make sure your Binance account is safe and compliant. Discover the fundamentals, appreciate the significance of KYC, and trade on one of the biggest cryptocurrency exchanges with confidence.
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...Aleksey Savkin
The Strategy Implementation System offers a structured approach to translating stakeholder needs into actionable strategies using high-level and low-level scorecards. It involves stakeholder analysis, strategy decomposition, adoption of strategic frameworks like Balanced Scorecard or OKR, and alignment of goals, initiatives, and KPIs.
Key Components:
- Stakeholder Analysis
- Strategy Decomposition
- Adoption of Business Frameworks
- Goal Setting
- Initiatives and Action Plans
- KPIs and Performance Metrics
- Learning and Adaptation
- Alignment and Cascading of Scorecards
Benefits:
- Systematic strategy formulation and execution.
- Framework flexibility and automation.
- Enhanced alignment and strategic focus across the organization.
Call8328958814 satta matka Kalyan result satta guessing➑➌➋➑➒➎➑➑➊➍
Satta Matka Kalyan Main Mumbai Fastest Results
Satta Matka ❋ Sattamatka ❋ New Mumbai Ratan Satta Matka ❋ Fast Matka ❋ Milan Market ❋ Kalyan Matka Results ❋ Satta Game ❋ Matka Game ❋ Satta Matka ❋ Kalyan Satta Matka ❋ Mumbai Main ❋ Online Matka Results ❋ Satta Matka Tips ❋ Milan Chart ❋ Satta Matka Boss❋ New Star Day ❋ Satta King ❋ Live Satta Matka Results ❋ Satta Matka Company ❋ Indian Matka ❋ Satta Matka 143❋ Kalyan Night Matka..
How MJ Global Leads the Packaging Industry.pdfMJ Global
MJ Global's success in staying ahead of the curve in the packaging industry is a testament to its dedication to innovation, sustainability, and customer-centricity. By embracing technological advancements, leading in eco-friendly solutions, collaborating with industry leaders, and adapting to evolving consumer preferences, MJ Global continues to set new standards in the packaging sector.
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
How to Implement a Real Estate CRM SoftwareSalesTown
To implement a CRM for real estate, set clear goals, choose a CRM with key real estate features, and customize it to your needs. Migrate your data, train your team, and use automation to save time. Monitor performance, ensure data security, and use the CRM to enhance marketing. Regularly check its effectiveness to improve your business.
The Genesis of BriansClub.cm Famous Dark WEb PlatformSabaaSudozai
BriansClub.cm, a famous platform on the dark web, has become one of the most infamous carding marketplaces, specializing in the sale of stolen credit card data.
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
𝐔𝐧𝐯𝐞𝐢𝐥 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐄𝐧𝐞𝐫𝐠𝐲 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐰𝐢𝐭𝐡 𝐍𝐄𝐖𝐍𝐓𝐈𝐃𝐄’𝐬 𝐋𝐚𝐭𝐞𝐬𝐭 𝐎𝐟𝐟𝐞𝐫𝐢𝐧𝐠𝐬
Explore the details in our newly released product manual, which showcases NEWNTIDE's advanced heat pump technologies. Delve into our energy-efficient and eco-friendly solutions tailored for diverse global markets.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night
2. Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
1.4 What Are Vaccines?
2. Overview of Vaccines Market, 2013-2023
2.1 Vaccines Market to Continue to Perform Strongly to 2023
2.2 Paediatric Vaccines Remain Central to Market
2.2.1 Adult Vaccination and Therapeutic Vaccines the Major Drivers to 2023
2.3 What Diseases and Technologies Drive the Market in 2013?
2.3.1 Ancillary Technologies
2.4 Pfizer’s Prevnar Leads the Market in 2013
2.5 Top Three Companies Held 52% of Market in 2012
2.5.1 Sanofi Pasteur: Leading Paediatric Portfolio
2.5.2 GlaxoSmithKline: a Strong Presence in Every Segment
2.5.3 Merck: Zostavax Revival Boosts 2012 Performance
2.5.4 Pfizer: A Major Player on the Strength of Prevnar
2.5.5 Novartis: Vaccines Business to be Divested?
2.5.6 Other Players in the Market: A Crowded Second Tier
2.5.6 Other Players in the Market2.8.1 The Vaccines Market
3. Paediatric Vaccines Segment, 2013-2023
3.1 Segment to Lose Market Share, but Still Record Strong Growth
3.2 Combinations Form Basis of Segment Revenues
3.3 Prevnar Franchise Represents a Quarter of the Paediatric Segment’s Total Value in 2012
3.3.1 Prevnar-13: Domination to Continue?
www.visiongain.com
3. Contents
3.3.1.1 First of the Blockbuster Vaccines
3.3.1.2 Label Extensions for Prevnar Continue
3.3.1.3 Synflorix Competing Strongly in Emerging Markets
3.3.1.4 Big Three Vaccine Manufacturers All Set to Challenge Pfizer in Pneumococcal Disease
Area
3.3.1.5 How Much Room for Growth for Prevnar-13?
3.3.2 Sanofi Pasteur and GlaxoSmithKline Competing in Paediatric Combination Space
3.3.2.1 Hexaxim Boosts Sanofi Portfolio
3.3.2.2 GlaxoSmithKline Combinations Make Gains in US in 2012
3.3.2.3 Inadequacies in Pertussis and Hepatitis B Care
3.3.2.4 Room for Vaccine Competition in Those Disease Areas?
3.3.2.5 Sanofi and GSK Head-to-Head, 2013-2023
3.3.3 Competition Increases in Meningitis Vaccines Space
3.3.3.1 Menveo Label Widened in August 2013
3.3.3.2 Other Competitors for Paediatric A, C, Y and W-135 Serotypes Market
3.3.3.3 Bexsero Still to Convince EU Payers
3.3.4 Four-Disease Combination is Merck’s Leading Paediatric Vaccine
3.3.4.1 Supply Issues Still Restraining ProQuad
3.3.4.2 Varivax Commercial Backbone of Combination
3.3.4.3 Mumps Immunity Waning?
3.3.4.4 Will MMR-II/ProQuad/Varivax Realise its Full Market Potential?
3.3.5 Duel for the Rotavirus Market Continues
3.3.5.1 RotaTeq Leads the Market
3.3.5.2 Rotavirus Immunisation Added to UK Schedules
3.3.5.3 New Chinese and Indian Products Come to Developing World
3.3.5.4 Will RotaTeq Hit the Blockbuster Heights?
3.3.6 Paediatric Vaccines Against Other Diseases, 2013
3.3.6.1 Japanese Encephalitis Vaccine Approved for Children
3.3.6.2 Mosquirix Records Disappointing Phase 3 Data
3.3.6.3 Sanofi Records a First in 50 Years of Dengue Research
www.visiongain.com
4. Contents
3.3.6.4 Two MedImmune RSV Vaccines in Development
3.3.6.5 Novartis Targeting Typhoid Opportunity
3.3.6.6 Hand, Foot and Mouth Vaccine: A Chinese Target
3.3.6.7 Anthrax Vaccines for Children?
3.3.6.8 Potential Vaccines for Autism and Diabetes
3.4 Summary: The Biggest Segment, but the Least Dynamic
4. Influenza Vaccines Segment, 2013-2023
4.1 New Pandemics Offer Biggest Growth Opportunities to 2023
4.2 Major Seasonal and Pandemic Vaccine Opportunities Remain
4.3 Abbvie and AstraZeneca Among the Segment’s Big Players
4.3.1 Sanofi has the Largest Influenza Franchise
4.3.1.1 Seasonal Vaccines Dominate the Franchise
4.3.1.2 Quadrivalent Product Will Bolster Steady Growth for the Fluzone-Led Franchise
4.3.1.3 Novartis’ Portfolio Leads the Seasonal Influenza Competition
4.3.1.4 GlaxoSmithKline and AstraZeneca Also Competing
4.3.1.5 Merck to Join the Seasonal Market Leaders?
4.3.2 Differentiating Seasonal Influenza Vaccines
4.3.2.1 CDC Promises Redesign of Influenza Vaccine Coverage
4.3.2.2 FDA Endorses Quadrivalents for the First Time in 2013
4.3.2.3 Cell Culture and Baculovirus-Derived Products Join the Market
4.3.2.4 Significant Scope for Enlarging the Patient Population
4.3.2.5 VLP, VERO and Intranasal Candidates in Pipeline
4.3.3 Threat and Opportunity: the Pandemic Influenza Space
4.3.3.1 H5N1: The Main Target
4.3.3.2 Novavax’s VLP Product Among the Leading H5N1 Candidates
4.3.3.3 H1N1: New Options for Post-Pandemic Strain
4.3.3.4 Pandemic H9N2: A Continuous Background Risk
4.3.3.5 H7N9: New Pandemic Threat in 2013
www.visiongain.com
5. Contents
4.3.3.6 Response to H7N9 Beyond China and Taiwan
4.3.4 Universal Influenza Vaccines: A Distant Dream?
4.3.4.1 Universal Candidates Reach Phase 2
4.4 Overview: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed
5. Adult Prophylactic Vaccines Segment, 2013-2023
5.1 Prevnar Approval to Boost the Segment to 2023
5.2 Routine Adult Vaccination to Become a Reality by 2023?
5.3 Gardasil Represented Nearly a Fifth of Segment Revenues in 2012
5.3.1 Gardasil Dominating HPV Disease Area
5.3.1.1 Cervarix Declines as Japan Catches Up in 2012
5.3.1.2 New Markets for Gardasil
5.3.1.3 Is There a Need for V503?
5.3.1.4 GlaxoSmithKline and Merck to Continue Dominating this Space
5.3.1.5 Gardasil’s Prospects Depend on its Successor
5.3.2 GlaxoSmithKline Continues to Dominate Hepatitis Vaccine Space
5.3.2.1 Few Competitors Beside Merck’s Recombivax
5.3.2.2 China Market Key for GlaxoSmithKline’s Hepatitis Vaccines
5.3.2.3 FDA Rejects Dynavax’s Heplisav Citing Safety Concerns
5.3.2.4 Hepatitis C A Major Pipeline Target
5.3.2.5 Engerix and Other GlaxoSmithKline Products to Continue Growing Through 2017
5.3.3 Reimmunisation against Pneumococcal, Meningococcal Disease
5.3.3.1 Menveo and Nimenrix Sanofi’s Main Challengers
5.3.3.2 Pfizer and JN-International Have Pipeline Candidates
5.3.3.3 How Big is the Adult Pneumonia Potential Market?
5.3.3.4 Sanofi Leads Booster Vaccination Space
5.3.3.5 Pertussis and TB Major Unaddressed Needs
5.3.4 Shingles Market Remains Relatively Untapped
5.3.4.1 Will Zostavax’s Revival Continue?
www.visiongain.com
6. Contents
5.3.4.2 Two New Late-Stage Shingles Candidates
5.3.4.3 Other Herpesvirus R&D in Vaccines
5.3.4.4 Need for Cytomegalovirus Vaccine?
5.3.5 Other Unmet Needs in the Adult Segment
5.3.5.1 Dengue Fever the Next Target
5.3.5.2 Anthrax and Other Bio-Terror Vaccines
5.3.5.3 HIV Vaccine: 30-Year Hunt Continues After HVTN 505
5.3.5.4 Developers’ Interest in Malaria
5.3.5.5 Anti-Staphyloccocal Vaccines Form an Important Need
5.3.5.6 Other New Antibacterial Vaccines in Development
5.3.5.7 Important New Antiviral Vaccine Targets
5.3.5.8 Protozoans and Other Vaccine Targets
5.4 Overview: Extensive Pipeline, but Adult Immunisation Still Needs to Become More Widely
Established
6. Therapeutic Vaccines Segment, 2013-2023
6.1 The Fastest-Growing Segment to 2023
6.2 The Future for Vaccines R&D?
6.3 Anti-Allergy Vaccines Make Up Bulk of Segment in 2012
6.3.1 Provenge: Troubled Segment Leader
6.3.1.1 Competition and Patient Doubt Undermine Provenge
6.3.1.2 Future Sales Growth for Dendreon?
6.3.1.3 Two Phase 3 Allogeneic Vaccines to Provide Competition
6.3.1.4 NorthWest Biotherapeutics Following Oxford BioMedica Out of the Race?
6.3.1.5 Products in Development in Ten Areas of Oncology
6.3.2 Novarx Heads Lung Cancer Hunt After Failure of Stimuvax
6.3.2.1 Lucanix Leads the Way
6.3.2.2 MAGE-A3 Also in Late-Stage Trials
6.3.2.3 Stiff Competition for MAGE-A3 in Melanoma Pipeline
www.visiongain.com
7. Contents
6.3.2.4 Agenus In Late-Stage Trials in Melanoma and Renal Cancer
6.3.3 Other Major Solid Tumour Targets
6.3.3.1 Breast Cancer One of the Most-Crowded Areas of Therapeutic Vaccines Pipeline
6.3.3.2 Pancreatic Cancer: Major Unmet Need, Slender Pipeline
6.3.3.3 Still Several Ovarian Cancer Candidates After Abagovamab Disappointment
6.3.3.4 Several Candidates Against Glioblastoma
6.3.3.5 Other Cancer Vaccines in Development
6.3.4 Other Chronic Diseases: Vaccine Treatments for RA and Diabetes?
6.3.4.1 New Options in Chronic Neurodegenerative Diseases Pipeline
6.3.4.2 HIV: Major Therapeutic Vaccines Target
6.3.4.3 Other Chronic Viral Infections Pipeline
6.3.4.4 Cat Allergies and Other New Allergy Targets for Vaccine R&D
6.3.4.5 Addictions and Other Therapeutic Vaccine Targets
6.4 Overview: Huge Potential, but Little Market Success to Date
7. Leading National Vaccines Markets, 2013-2023
7.1 US and EU5 Represent Over 70% of Market
7.2 The US Remains the Foundation of the Global Market in 2013
7.3 Strong Pro-Immunisation Stance in US
7.4 EU5: Medical Need Vies with Austerity Economics
7.5 Japan: Low Existing Coverage Means High Market Potential
7.6 BRIC Nations: To Overtake EU5 in Market Share by 2023
7.7 Rest of the World: Unmet Needs Remain
8. Qualitative Industry Analysis, 2013
8.1 Vaccines Expand in Importance for Pharmaceutical Industry
8.2 Weaknesses: Many Challenges in this Sector
8.3 Opportunities: MRSA, HIV, and Other Unmet Needs Remain
www.visiongain.com
8. Contents
8.4 Threats: Cost-Effectiveness a Harder Sell for Governments
8.5 Social Concerns: One of the Most Emotive Areas of Healthcare
8.6 Technological Developments: New Delivery Systems, New Adjuvants, 2D Barcoding and
Other Innovations
8.7 Health Economics: 2700% Increase in Cost of Vaccinating a Child
8.8 Political Issues: From Bio-Defence to Polio Eradication, Governments Hold the Key to the
Market
9. Research Interviews, 2013
9.1 Interview with Dr. Louis J. Picker, Oregon Health and Science University
9.1.1 Challenges of DNA/Ad Vector Vaccines
9.1.2 Broadly Neutralising Antibodies for HIV
9.1.3 A Third Way? The T-Cell Vaccine Approach
9.1.4 Combinations and Other Strategies for HIV
9.1.5 Getting to the Clinic with Therapeutic and Prophylactic HIV Vaccines
9.2 Interview with Tamar Ben-Yedidia, PhD, Chief Scientific Officer, and Tanya Gottlieb, PhD,
Business Development, BiondVax Pharmaceuticals
9.2.1 Progress of BiondVax’s Candidate Vaccine
9.2.2 Trialling the Vaccine as a Primer
9.2.3 Assays for Universal Vaccine Effectiveness
9.2.4 Key Differentiators for BiondVax’s Candidate
10. Conclusions
10.1 Vaccines Market Remains on Course for Steady Growth to 201
10.2 Sales Growth to Be Sustained 2018-2023
10.3 Adult Segment to Grow Twice as Fast as Paediatric Segment
10.4 Therapeutic Vaccines to Gain Importance from 2018-2023
10.5 Market Remains Heavily Consolidated
10.6 Blockbuster Products Lead the Way; Scope in Developing World
10.7 Rich Pipeline, Particularly in Therapeutic Vaccines
www.visiongain.com
12. Contents
Table 5.7 Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), AGR (%), CAGR (%), 20122017
Table 5.8 Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), AGR (%), CAGR (%), 20182023
Table 5.9 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), AGR (%), CAGR
(%), 2012-2017
Table 5.10 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), AGR (%),
CAGR (%), 2018-2023
Table 5.11 Selected Pipeline Meningitis Vaccines, 2013
Table 5.12 Selected Pipeline Pneumonia Vaccines, 2013
Table 5.13 Selected Pipeline TB, Diphtheria, Pertussis, Tetanus and Rotavirus Adult Vaccines,
2013
Table 5.14 Zostavax: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.15 Zostavax: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.16 Selected Pipeline for Herpesvirus Vaccines, 2013
Table 5.17 Selected Pipeline for New Adult Vaccines for Currently Vaccine-Preventable Diseases,
2013
Table 5.18 Selected Pipeline for Dengue Virus Vaccines, 2013
Table 5.19 Selected Pipeline for Anthrax and Other Potential Bio-Terrorism Agents Vaccines,
2013
Table 5.20 Selected Pipeline for HIV Vaccines, 2013
Table 5.21 Selected Pipeline for Malaria Vaccines, 2013
Table 5.22 Selected Pipeline for New Antibacterial Vaccines, 2013
Table 5.23 Selected Pipeline for New Antiviral Vaccines, 2013
Table 5.24 Selected Pipeline for Other New Adult Prophylactic Vaccines, 2013
Table 6.1 Therapeutic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.2 Therapeutic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.3 Leading Therapeutic Vaccine Products: Revenues ($m), Segment Market Share (%),
2012
Table 6.4 Selected Therapeutic Vaccines, 2013
www.visiongain.com
13. Contents
Table 6.5 Selected Pipeline Prostate Cancer Therapeutic Vaccines, 2013
Table 6.6 Selected Pipeline Lung Cancer Therapeutic Vaccines, 2013
Table 6.7 Selected Pipeline Melanoma Therapeutic Vaccines, 2013
Table 6.8 Selected Pipeline Renal Cancer Therapeutic Vaccines, 2013
Table 6.9 Selected Pipeline Colorectal Cancer Therapeutic Vaccines, 2013
Table 6.10 Selected Pipeline Haematological Cancer Therapeutic Vaccines, 2013
Table 6.11 Selected Pipeline Breast Cancer Therapeutic Vaccines, 2013
Table 6.12 Selected Pipeline Pancreatic Cancer Therapeutic Vaccines, 2013
Table 6.13 Selected Pipeline Ovarian Cancer Therapeutic Vaccines, 2013
Table 6.14 Selected Pipeline Brain Cancer Therapeutic Vaccines, 2013
Table 6.15 Selected Other Cancer Therapeutic Vaccines, 2013
Table 6.16 Selected RA and Diabetes Therapeutic Vaccines, 2013
Table 6.17 Selected AD and MS Therapeutic Vaccines, 2013
Table 6.18 Selected HIV Therapeutic Vaccines, 2013
Table 6.19 Selected Other Chronic Viral Infections Therapeutic Vaccines, 2013
Table 6.20 Selected Anti-Allergy Therapeutic Vaccines, 2013
Table 6.21 Selected Other Therapeutic Vaccines, 2013
Table 7.1 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2012
Table 7.2 Vaccines Market by Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%),
2012-2017
Table 7.3 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2017
Table 7.4 Vaccines Market by Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%),
2018-2023
Table 7.5 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2023
Table 8.1 World Vaccines Market: Strengths and Weaknesses, 2013
Table 8.2 World Vaccines Market: Opportunities and Threats, 2013
Table 8.3 World Vaccines Market: STEP Analysis, 2013-2023
www.visiongain.com
14. Contents
List of Figures
Figure 2.1 Vaccines Market: Revenues ($m), 2012-2023
Figure 2.2 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Figure 2.3 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Figure 2.4 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Figure 2.5 Vaccines Market Breakdown by Segment: Revenues ($m), 2012-2023
Figure 2.6 Vaccines Market Breakdown by Segment: Revenues ($m), 2012, 2017, 2023
Figure 2.7 Leading Vaccine Products: Revenues ($m), Market Share (%), 2012
Figure 2.8 Leading Vaccine Products: Revenues ($m), 2012-2023
Figure 2.9 Leading Vaccine Manufacturers: Revenues ($m), Market Share (%), 2012
Figure 3.1 Paediatric Vaccines Segment: Revenues ($m), 2012-2023
Figure 3.2 Global Mortality Due to VPDs in Children Under Five, Breakdown by Disease (%),
2008
Figure 3.3 Leading Paediatric Vaccine Products: Revenues ($m), Segment Market Share (%),
2012
Figure 3.4 Leading Paediatric Pneumococcal Vaccine Products: Market Share (%), 2012
Figure 3.5 Prevnar Revenue Breakdown by Segment (Paediatric and Adult Prophylactic):
Revenues ($m), 2012-2023
Figure 3.6 Pentacel/Pediacel/Pentaxim/Others; Infanrix/Pediarix/Others: Revenues ($m), 20122023
Figure 3.7 ProQuad/ MMR-II/ Varivax: Revenues ($m), 2012-2023
Figure 3.8 Division of Rotavirus Vaccine Market (%), 2012
Figure 3.9 RotaTeq: Revenues ($m), 2012-2023
Figure 3.10 Drivers and Restraints for Paediatric Vaccines, 2013
Figure 4.1 Influenza Vaccines Segment: Revenues ($m), 2012-2023
Figure 4.2 Leading Influenza Vaccine Products: Revenues ($m), Segment Market Share (%),
2012
Figure 4.3Fluzone/Panenza/Humenza/Intanza/ IDflu/Emerflu/Others: Breakdown by Seasonal and
Pandemic Revenues ($m), 2010-2012
www.visiongain.com
15. Contents
Figure 4.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($m), 2012-2023
Figure 4.5 Drivers and Restraints for Influenza Vaccines, 2013
Figure 5.1 Adult Prophylactic Vaccines Segment: Revenues ($m), 2012-2023
Figure 5.2 Leading Adult Prophylactic Vaccine Products: Revenues ($m), Segment Market Share
(%), 2012
Figure 5.3 Division of HPV Vaccine Market (%), 2012
Figure 5.4 Gardasil: Revenues ($m), 2012-2023
Figure 5.5 Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), 2012-2023
Figure 5.6 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), 2012-2023
Figure 5.7 Zostavax: Revenues ($m), 2012-2023
Figure 5.8 Drivers and Restraints for Adult Prophylactic Vaccines, 2013
Figure 6.1 Therapeutic Vaccines Segment: Revenues ($m), 2012-2023
Figure 6.2 Leading Therapeutic Vaccine Products: Revenues ($m), Segment Market Shares (%),
2012
Figure 6.3 Drivers and Restraints for Therapeutic Vaccines, 2013
Figure 7.1 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2012
Figure 7.2 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2017
Figure 7.3 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2023
Figure 7.4 Vaccines Market Breakdown by Region: Revenues ($m), 2012-2023
Figure 7.5 Vaccines Market Breakdown by Regional Bloc: Revenues ($m), 2012-2023
Figure 7.6 Vaccines Market Breakdown by Region: Revenues ($m), 2012, 2017, 2023
Figure 7.7 US Vaccines Market: Revenues ($m), 2012-2023
Figure 7.8 EU5 Vaccines Market: Revenues ($m), 2012-2023
Figure 7.9 Japanese Vaccines Market: Revenues ($m), 2012-2023
Figure 7.10 BRIC Nations Vaccines Market: Revenues ($m), 2012-2023
Figure 7.11 Rest of the World Vaccines Market: Revenues ($m), 2012-2023
Figure 10.1 World Vaccines Market: Revenues ($m), 2012-2017
Figure 10.2 World Vaccines Market: Revenues ($m), 2018-2023
Figure 10.3 World Vaccines Market, Breakdown by Segment: Revenues ($m), 2012-2017
Figure 10.4 World Vaccines Market, Breakdown by Segment: Revenues ($m), 2018-2023
www.visiongain.com
16. Contents
Organisations Mentioned in Report
Abbott Laboratories
Aaron Diamond AIDS Research Center
Abbott Laboratories
AbbVie
Acambis
ACE Biosciences
Activartis Biotech
Adamis Pharmaceuticals
Aduro BioTech
Advaxis
Aeras
Aeras Global TB Vaccine Foundation
Affiris
Agency for Science, Technology and Research (Singapore)
Agenus
Akela Pharma
ALK Abello
Allergy Therapeutics
Allertein Therapeutics
Alnylam
AlphaVax
Altravax
American Academy of Pediatrics
Amgen
Antigen Discovery
Antigen Express
Antigenics
Argos Therapeutics
Astellas Pharma
www.visiongain.com
17. Contents
AstraZeneca
Augmenta Biologicals
AuRx
AVAX Technologies
Baxter Healthcare
Bayer HealthCare
Bayhill Therapeutics
Beijing Key Yuan Xinhai Pharmaceutical
Beijing Vigoo Biological
Bellicum Pharmaceuticals
Bharat Biotech
Biken Japan
Bill & Melinda Gates Foundation
Bio-Manguinhos
BiondVax
Bionor Pharma
BioNTech
BioSante Pharmaceuticals
Biotech Synergy
Biovest International
BN ImmunoTherapeutics (Bavarian Nordic)
Boston Children's Hospital
BravoBio
Butantan
Cadila Pharma
Cancer Advances
Celldex Therapeutics
CEL-SCI
Celtic Pharma
Center of Molecular Immunology (Cuba)
www.visiongain.com
18. Contents
Centers for Disease Control (CDC)
CG Therapeutics
Chemo-Sero-Therapeutic Research Institute
Chengdu Institute
China National Biotech Group (CNBG)
China NT Pharma Group
Chinese Centre for Disease Control
Chinese State Food and Drug Administration (SFDA)
Chiron
Circassia
Colby Pharmaceutical
Columbia University
Cosmo Pharmaceuticals
Crucell
CSL Biotherapies
Cuba’s Center of Molecular Immunology
CureVac
Cytokine PharmaSciences
Cytos Biotechnology
Daiichi Sankyo
DBV Technologies
Dendreon
Denka Seiken Company
Desmond Tutu TB Centre
Diabetes UK
Diamyd
Dynavax
DynPort Vaccine Company
Eisai
Elea Laboratories
www.visiongain.com
19. Contents
EMD Serono
Emergent BioSolutions
Endocyte
Epeius Biotechnologies
Erasmus Medical Centre
Etubics
European Medicines Agency (EMA)
Evans Medical
Food and Drug Administration (US FDA)
Galena Biopharma
GAVI Alliance
GE Healthcare
GeneCure Biotechnologies
Genetic Immunity
Genocea Biosciences
GenPhar
GenVec
GeoVax Labs
Geron
GlaxoSmithKline (GSK)
Glide Pharma
Gliknik
Global Health Innovative Technology Fund (GHIT Fund)
GlobeImmune
Gradalis
Greer Laboratories
Hawaii Biotech
Health Protection Agency (HPA)
Heat Biologics
Helmholtz Centre for Infection Research
www.visiongain.com
20. Contents
iBio
Ichor Medical Systems
immatics biotechnologies
Immune Response Biopharma
Immune Targeting Systems
Immunitor
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
Immunomic Therapeutics
Immunotope
Immunovaccine
Immunovative Therapies
ImmusanT
Infectious Diseases Research Institute
Inovio Pharmaceuticals
Intercell
Intercell USA
International AIDS Vaccine Initiative (IAVI)
International Federation of Pharma Manufacturers and Associations (IFPMA)
International Medica Foundation
Inviragen
J. Craig Venter Institute
Janssen Alzheimer Immunotherapy
JN-International Medical
Johnson & Johnson
Joint Committee on Vaccination and Immunisation (JCVI, UK)
KAEL-GemVax
Karolinska Institute
Kitasato Institute
www.visiongain.com
21. Contents
Korean Ministry of Health and Welfare
La Jolla Institute for Allergy & Immunology
Life Technologies
LigoCyte Pharmaceuticals
Liquidia Technologies
London School of Hygiene and Tropical Medicine
MabVax Therapeutics
Max Planck Society
MaxCyte
Medecins Sans Frontieres (MSF)
Medicago
MedImmune
Memgen
Menarini
Merck & Co.
Merck Serono
Meridian Biosciences
Mitsubishi Tanabe Pharma
Momotaro-Gene
Nabi Biopharmaceuticals
NanoBio
Nanotherapeutics
National Administration of Medicines, Food and Medical Technology (ANMAT, Argentina)
Natrix Separations
NewLink Genetics
Northwest Biotherapeutics
Novadigm Therapeutics
Novartis
NovaRx
Novavax
www.visiongain.com
22. Contents
Novo Energies
Nuron Biotech
NuVax Therapeutics
Nypro Healthcare
Okairos
OncoPep
Oncothyreon
Opal Therapeutics
Opexa Therapeutics
Opko Health
Optimer Pharmaceuticals
Orban Biotech
Oregon Health and Science University, Vaccine and Gene Therapy Institute
Oxford BioMedica
PaxVax
Petrovax
Pfizer
PharmAthene
Pique Therapeutics
Polynoma
Prima Biomed
Profectus Biosciences
Progenics Pharmaceuticals
Protein Sciences
PsiOxus Therapeutics
Quantum Immunologics
Quest PharmaTech
Sanaria
Sanofi
Sanofi Pasteur
www.visiongain.com
23. Contents
Sarepta
SciVac
Scripps Research Institute
Selecta Biosciences
Serum Institute of India
Shanghai BravoBio
Shanghai Pharma
Shantha Biotech
Shionogi
Sinopharm Group
Sinovac Biotech
Soligenix
South African Tuberculosis Vaccine Initiative (SATVI)
Stallergenes
Stemline Therapeutics
Sumagen
Sunovion Pharmaceuticals
Takeda
TapImmune
TD Vaccines
Tekmira
Tesco
Tetragenetics
Teva Pharmaceutical industries
Theraclone Sciences
Thymon
Topaz Pharmaceuticals
Transgene
TVAX Biomedical
UK Joint Committee on Vaccination and Immunisation
www.visiongain.com
24. Contents
UMN Pharma
UNICEF
United Biomedical
Universidad de Chile
Université Laval
University of Cape Town
University of Guelph
University of London
University of Minnesota's Centre for Infectious Disease Research and Policy
University of Queensland
University of Toronto
US National Biodefence Science Board
US Naval Medical Research Center
Utrecht University
Vaccine Research Center (NIAID)
Vaccine Technologies
Vaccinogen
Vakzine Projekt Management
Valneva
Vanderbilt University
Vaxart
Vaxin
VaxInnate
VaxOnco
Vical
Vivalis
Vodafone
Walter Reed Army Institute
World Health Organisation (WHO)
Xcellerex
www.visiongain.com
26. World Vaccines Market 2013-2023
phase 3 studies on the candidate, the largest of which is a head-to-head comparison of Gardasil
and V 503 in 14,000 women. Merck announced in 2013 it is extending the clinical trials of V503
since too few patients in the Gardasil arm of the trial have developed HPV infections. This implies
that there is no medical need to vaccinate against additional subtypes of HPV; Gardasil alone
appears to offer adequate protection.
5.3.1.4 GlaxoSmithKline and Merck to Continue Dominating this Space
In addition to V503, Merck has an octavalent candidate VLP-based candidate, V502. This product
completed phase 1 studies, with a phase 2 trial being withdrawn prior to enrolment in 2012,
presumably because Merck’s R&D focus is on the more-advanced V503 candidate. Genticel is
developing a therapeutic vaccine, ProCervix, for high-risk HPV patients; Inovio also has a
therapeutic DNA vaccine candidate, VGX-3100, in development. These therapeutic vaccines are
dealt with in the following chapter. In terms of preventive vaccines, GlaxoSmithKline seems set to
remain the only challenger to Merck in the HPV space.
5.3.1.5 Gardasil’s Prospects Depend on its Successor
Although Gardasil’s revenues will fluctuate, visiongain anticipates that the product broadly faces a
decline based on its relative maturity and the likelihood of competition from the V-503 follow-on. If
further clinical data shows no rationale for transitioning patients to the nine-valent franchise
extension, Gardasil may continue to enjoy market dominance. Visiongain’s prediction here is
based on the likelihood that clinical data will ultimately justify the transition to V-503, with
consequent cannibalisation of Gardasil revenues. By 2017, visiongain estimates these revenues
will decline to $1429m. By 2023, general substitution of V-503 will see Gardasil’s revenues fall to
$650m, visiongain believes. See Table 5.5, Table 5.6, and Figure 5.4.
Table 5.5 Gardasil: Revenues ($m), AGR (%), CAGR (%), 2012-2017
2012
Revenues ($m )
AGR (%)
CAGR (%,2012-2017)
2013
2014
2015
2016
2017
1895
1755
1823
1875
1581
1429
-7
4
3
-16
-10
-5
Source: visiongain 2013
www.visiongain.com
Page 105
27. World Vaccines Market 2013-2023
Table 5.6 Gardasil: Revenues ($m), AGR (%), CAGR (%), 2018-2023
2018
2019
2020
2021
2022
2023
Revenues ($m )
1276
1101
929
725
680
650
AGR (%)
-11
-14
-16
-22
-6
-4
CAGR (%, 2018-2023)
-13
CAGR (%, 2012-2023)
-9
Source: visiongain 2013
Figure 5.4 Gardasil: Revenues ($m), 2012-2023
2000
1800
Revenues ($m)
1600
1400
1200
1000
800
600
400
200
0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Year
Source: visiongain 2013
5.3.2 GlaxoSmithKline Continues to Dominate Hepatitis Vaccine Space
GlaxoSmithKline’s hepatitis vaccines account for ~85% of the hepatitis vaccines market. As noted,
hepatitis B is widely included in paediatric combinations. Of GlaxoSmithKline’s other vaccines,
Twinrix offers inoculation against hepatitis A and hepatitis B to patients 18 years of age or over,
and comes in preservative-free liquid form for intramuscular injection. GlaxoSmithKline also
markets separate vaccines for hepatitis A (Havrix) and hepatitis B (Engerix-B, a recombinant
subunit vaccine supplied in refrigerated, preservative-free liquid form or in pre-filled syringes, and
its reformulation Fendrix for patients aged 15 years or over).
www.visiongain.com
Page 106